Nipple-sparing mastectomies: Clinical outcomes from a single academic institution

Barbara Dull  
Washington University School of Medicine in St. Louis

Leah Conant  
Washington University School of Medicine in St. Louis

Terence Myckatyn  
Washington University School of Medicine in St. Louis

Marissa Tenenbaum  
Washington University School of Medicine in St. Louis

Amy Cyr  
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Dull, Barbara; Conant, Leah; Myckatyn, Terence; Tenenbaum, Marissa; Cyr, Amy; and Margenthaler, Julie A., "Nipple-sparing mastectomies: Clinical outcomes from a single academic institution." Molecular and Clinical Oncology. 6(5), 737-742. (2017). https://digitalcommons.wustl.edu/open_access_pubs/5876

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Abstract. Nipple-sparing mastectomies (NSMs) are increasingly used in the surgical treatment of patients with breast cancer and for prevention of breast cancer. The present study was performed to review the outcomes of patients undergoing NSMs at a single large university setting. A retrospective chart review was performed on all patients undergoing NSMs from 2008-2014. Charts were reviewed for demographic data and patient characteristics. Tumor and breast size, cancer recurrence and complications were also evaluated. Descriptive statistics were utilized to summarize the findings. From 2008-2014, 110 patients underwent 197 NSMs. The mean patient age was 44.4 years (range, 20-77). The average body mass index was 24 (range, 18-47). Breast weight was available for 106 specimens, with a mean weight of 475.5 g (range, 124.1-1,625.0 g). Seventy-three NSMs were performed for cancer and 124 were performed prophylactically. The mean tumor width was 1.38 cm (range, 0-6.0 cm), with an average nipple to tumor distance of 5.87 cm (range, 2.93-10.0 cm). Three (4%) patients required removal of the nipple areolar complex (NAC) due to pathological extension of the tumor. A total of 34 (17.2%) complications occurred, including infections, hematomas and nipple necrosis, with 9 requiring removal of the NAC and 13 requiring removal of the tissue expander or implant. Smokers had a 36.0% (9/25) complication rate, compared with 14.5% (25/172) of nonsmokers (P<0.05). During follow-up, one recurrence was noted, located on the chest wall. There were no recurrences in the NAC group. Therefore, NSMs may safely be performed without compromising oncologic outcomes or increasing complication rates in properly selected patients.

Introduction

For nearly a century the standard surgical approach to treating breast cancer was to perform a Halstead radical mastectomy removing the breast, axillary lymph nodes and pectoralis muscle. It was believed that the more tissue that was removed the better the survival for the patient. This theory was disproven and surgeons began performing less invasive surgery in the 1970s and 1980s (1,2). With the publication of National Surgical Adjuvant Breast and Bowel Project protocol B-06, breast conserving surgery was determined to have equivalent results in terms of survival and local recurrence with the addition of radiation therapy, when compared with mastectomy (3). If deemed to be an appropriate candidate, patients have the choice between breast conserving surgery or mastectomy. The rates of breast conserving surgery have remained stable over the last decade, however the rates of women opting for contralateral prophylactic mastectomy have steadily increased for various reasons (4). For patients undergoing mastectomies, rates of reconstruction vary and ≤42% undergo this procedure (5). Traditionally, mastectomy with reconstruction for the treatment of breast cancer has been performed via a skin‑sparing approach, as first described by Toth and Lappert (6) in 1991. Nipple and skin‑sparing mastectomies, with preservation of the nipple-areola complex (NAC), have generally been performed for the treatment of benign disease and prophylactically in women at high risk for the development of breast cancer (7-9).

One of the concerns regarding the safety of nipple-sparing mastectomies (NSMs) in the treatment of breast cancer patients is the potential increased risk of breast cancer recurrence. The terminal duct lobular unit has been identified as the location for the development of all breast cancer, and a 2008 study identified the presence of terminal duct lobular units in the nipples of 9% of patients (10,11). The rate of occult malignancy detected in the NAC in mastectomy specimens has varied widely with studies reporting an incidence of 1-31% (12-16). Over the years, a number of prospective and retrospective studies have demonstrated a cancer recurrence rate in the NAC of up to 2%, with local recurrence rates ranging from 1-6% (17-19). A more recent meta-analysis comparing NSM to skin-sparing mastectomy (SSM) and/or modified radical mastectomy (MRM) identified no difference
in overall survival, disease free survival or local recurrence amongst the groups in properly selected patients with early stage breast cancer (20).

Overall complication rates for NSM have been reported to be as high as 60% in certain older studies, with more recent data suggesting complication rates of 16-22% (21-22). In a 2003 study published by Gerber et al (19) the complication rate of NSM was compared with SSM and MRM and the overall complication rates were 20, 20, and 18% respectively. Similar findings have been reported in more recent retrospective studies comparing NSM with SSM (16,21). With comparable complication and recurrence rates to SSM, more surgeons are offering NSM to patients as a more cosmically appealing alternative.

The current study was undertaken to evaluate the outcomes of patients undergoing NSMs at a single, large university hospital. Specifically, complication rates and tumor recurrence were studied.

Patients and methods

Patients. A prospectively maintained database of all surgical patients with breast cancer treated between September 2008 and June 2014 was queried following approval from the Washington University Institutional Review Board. A retrospective chart review was then undertaken for all patients who had undergone an NSM performed by one of two breast surgical oncologists with reconstruction performed by one of two plastic surgeons. Charts were reviewed for patient demographics, including age, body mass index (BMI) and smoking status. In those patients who underwent NSMs due to cancer, tumor characteristics were also recorded, including tumor size and nipple to tumor distance as well as tumor recurrence. All patients were required to have a tumor to nipple distance of >2 cm to be eligible for nipple-sparing mastectomy at our institution. The incision utilized, as well as the type of reconstruction undertaken were also evaluated. For all patients, any complications occurring within 30 days of surgery were documented, including any additional surgical procedures that were performed.

Statistical analysis. Statistical analysis was performed utilizing Fisher's exact test for categorical variables and student's unpaired t-test for continuous variables utilizing SPSS software version 22 (IBM SPSS, Armonk, NY, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Patient demographics. In the 6-year study period, 110 patients underwent 197 NSMs. Twenty-three (20.9%) patients had a unilateral NSM, while 87 (79.1%) went on to have bilateral NSMs. Of the 197 procedures performed, 124 (62.9%) were prophylactic and 73 (37.1%) were completed for cancer. Of the patients presenting with a breast cancer diagnosis, 25 (34.2%) had ductal carcinoma in situ (DCIS), 32 (43.8%) were TNM Stage I, 14 (19.2%) were TNM Stage II and 2 (2.8%) were TNM Stage III. Nine (8%) patients underwent neoadjuvant chemotherapy, 17 (15.5%) were treated with adjuvant chemotherapy and 3 (2.7%) underwent neoadjuvant and adjuvant chemotherapy. Two (1.8%) patients had undergone previous breast conserving therapy with radiation therapy. Ten (9%) patients underwent adjuvant chest wall radiation due to positive or close (<1 mm) margins or lymph node involvement on final pathology results.

The mean age of all patients undergoing surgery was 44.4 years (range, 20-77). Overall, the patients in the current study were at a healthy weight with an average BMI of 24, with a BMI range of 18-47. Breast weight was only documented for 106 specimens, with a mean weight of 475.5 g (range, 124.1-1,625.0 g). Thirteen (11.8%) of the patients studied were active smokers at the time of surgery.

Complications. The overall complication rate in this study was 17.3% (34/197; Table I). There was no statistically significant difference in complication rates based on patient age, BMI or breast weight. However, those patients who had complications were more likely to be smokers (26.5%) compared to patients without any complications (8.6%; P<0.05). Four of the patients who were smokers developed bilateral complications of infection and nipple necrosis. Thirteen patients underwent removal of their implant or tissue expander due to a complication and this was more common in smokers (25.0%) than nonsmokers (4.6%; P<0.05).

There was no difference in the rate of complications, whether the operation was performed prophylactically or as part of breast cancer treatment (Table I). We considered a positive nipple margin to be a complication; therefore those patients with a closer tumor to nipple distance on final pathology had a significantly higher complication rate (Table I). Of the patients with complications, 5 (14.7%) had undergone either prior chest wall radiation or adjuvant radiation compared with only 7 (4.3%) patients without complications (P<0.05). The most common complications were skin flap or nipple necrosis (12/34) and infection (11/34) (Table II). Five occurrences of necrosis required NAC reconstruction, 3 instances were extensive necrosis necessitating implant removal and an additional 2 required surgical revision of the incision. Of the 11 infections occurring in the 30-day postoperative period, 9 required removal of the implant and 1 patient required surgical revision of their wound. Five hematomas occurred postoperatively with 3 requiring surgery for evacuation of the hematoma and 1 necessitating implant removal. A single seroma occurred in the 30-day postoperative period, which was treated with needle aspiration. One patient developed flash pulmonary edema in the immediate postoperative period but had had bilateral NSMs and therefore was considered to have had two complications.

Surgical technique. Twenty-seven (13.7%) NSMs were completed via a circumareolar approach, 71 (36%) via a lateral breast incision and 99 (50.3%) utilizing an inframammary incision. There was no difference in overall complication rates among the three incision types utilized (Table I). However, when evaluating the 9 complications that resulted in loss of the NAC, there was a significant difference amongst the 3 incision types utilized (Table III). Seven of the 9 (77.8%) instances of NAC loss occurred following the use of a circumareolar incision compared to 1 (11.1%) loss each with the lateral and inframammary approaches (P<0.05). The removal of the
NAC that occurred after both a lateral and inframammary approach was due to DCIS behind the nipple, whereas only 1 NAC was removed following a circumareolar incision due to a positive nipple margin. The type of reconstruction performed did not affect complication rates (Table I). Overall, 106 (53.8%) patients underwent reconstruction with tissue expander placement and 91 (46.2%) received direct-to-implant based reconstruction. There was no difference in complication rate among patients receiving a tissue expander (16.9%) and direct implant (17.6%) (P>0.05). However, a significantly larger percentage of patients receiving a direct implant (10.9%) underwent implant removal due to a complication than those with placement of a tissue expander (2.8%; P<0.05).

Outcomes. In the first 3 years of the study, 44 NSMs were performed with 9 (20.5%) complications, compared with a complication rate of 16.3% (25/153) in the final 3 years of the study (P>0.05). The complication rate has steadily declined, with only 5/37 (13.5%) patients experiencing a complication occurring in the most recent six months of the study.

### Table I. Comparison of demographics, tumor characteristics and surgical data of patients undergoing nipple-sparing mastectomies with and without subsequent complications.

<table>
<thead>
<tr>
<th></th>
<th>No complications (n=163)</th>
<th>Complications (n=34)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient age, years (range)</td>
<td>44.1 (25-77)</td>
<td>43.6 (20-72)</td>
<td>NS</td>
</tr>
<tr>
<td>BMI (range)</td>
<td>25.2 (19.9-31.2)</td>
<td>23.7 (17.9-47.2)</td>
<td>NS</td>
</tr>
<tr>
<td>Smoker (%)</td>
<td>14 (8.6)</td>
<td>9 (26.5)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Prophylactic surgery (%)</td>
<td>105 (64.4)</td>
<td>19 (55.8)</td>
<td>NS</td>
</tr>
<tr>
<td>Stage (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>21 (12.9)</td>
<td>4 (11.8)</td>
<td>NS</td>
</tr>
<tr>
<td>I</td>
<td>26 (16)</td>
<td>6 (17.6)</td>
<td>NS</td>
</tr>
<tr>
<td>II</td>
<td>10 (6.1)</td>
<td>4 (11.8)</td>
<td>NS</td>
</tr>
<tr>
<td>III</td>
<td>1 (0.6)</td>
<td>1 (3)</td>
<td>NS</td>
</tr>
<tr>
<td>Breast weight, g (range)</td>
<td>458 (124-1625)</td>
<td>545 (170-836)</td>
<td>NS</td>
</tr>
<tr>
<td>Tumor size, cm (range)</td>
<td>1.5 (0-6)</td>
<td>1.0 (0-1.05)</td>
<td>NS</td>
</tr>
<tr>
<td>Tumor to nipple distance, cm (range)</td>
<td>5.87 (2.93-10.7)</td>
<td>5.23 (0-8.51)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Chest wall radiation</td>
<td>7 (4.3)</td>
<td>5 (14.7)</td>
<td>&lt;0.05</td>
</tr>
</tbody>
</table>

### Incision utilized

- Circumareolar: 19 (11.7) vs. 8 (23.5); NS
- Lateral: 62 (38.0) vs. 9 (26.5); NS
- Inframammary: 82 (50.3) vs. 17 (50); NS

### Reconstruction

- Tissue expander: 18 (52.9) vs. 88 (54); NS
- Direct to implant: 16 (47.1) vs. 75 (46); NS

*Patient data not available for 78 patients without complications and 13 patients with complications.

### Table II. All complications (n=34) and additional surgical procedures performed to correct the associated complication.

<table>
<thead>
<tr>
<th>Complication type</th>
<th>Number of complications</th>
<th>Additional procedures required (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive nipple margin</td>
<td>3</td>
<td>Removal of NAC (3)</td>
</tr>
<tr>
<td>Hematoma</td>
<td>5</td>
<td>Evacuation (3), implant removal (1)</td>
</tr>
<tr>
<td>Infection</td>
<td>11</td>
<td>Implant removal (9), wound revision (1)</td>
</tr>
<tr>
<td>Necrosis</td>
<td>12</td>
<td>NAC reconstruction (5), implant removal (3), revision of incision (2)</td>
</tr>
<tr>
<td>Seroma</td>
<td>1</td>
<td>Aspiration</td>
</tr>
<tr>
<td>Flash pulmonary edema</td>
<td>2</td>
<td>None</td>
</tr>
</tbody>
</table>

NAC, nipple areolar complex.
In the current study, those patients with a closer tumor to which is comparable with the reported literature (21,25,30,31). This may expand the indications for NSM in the 36-month median follow-up, no recurrences occurred in the

tumor recurrence within the NAC in the current study.

Discussion

The rate of local recurrence in numerous studies of patients undergoing an NSM varies, ranging from 0-25.7% (18,19,23,24). In the studies demonstrating rates of local recurrence >10%, cancer recurrence in the lymph nodes was included in the rate (19,24). Gerber et al (19) evaluated 246 patients with an indication for MRM who were treated with MRM, SSM or NSM with axillary lymph node dissection, identifying no differences in the rates of local recurrence amongst the three groups after a mean follow-up period of 101 months. More recent studies have demonstrated much lower local recurrence rates, similar to the present findings (16,24). An analysis of 1,006 procedures from the Italian National database of NSM, the local regional recurrence rate was 2.9% with a recurrence rate in the NAC of 0.7% (25). In the present study, a single recurrence occurred, yielding a local recurrence rate of 1.4%. This was a chest wall recurrence in a patient with stage I (T1N0) cancer who did not require adjuvant chemotherapy or radiation following NSM. No patients presented with recurrence in the NAC during the time period studied.

In order to decrease the likelihood of cancer involvement of the NAC, numerous studies have recommended that the tumor to NAC distance on pre-operative imaging be no closer than 2 cm (23,26-28). Tumors found to be closer than 2 cm to the NAC are considered to be a relative contraindication to pursuing NSM. The lower local recurrence rate in the current study is likely due in large part to patient selection, as there was a requirement that all imaging demonstrate a distance >2 cm between the tumor and the NAC. A previous study by Tang et al (29) evaluated their group’s experience with positive nipple margins and management, including excision of only the nipple with retention of the areola, and identified that at a 36-month median follow-up, no recurrences occurred in the nipple/NAC. This may expand the indications for NSM in the future.

The complication rate in the present study was 17.3%, which is comparable with the reported literature (21,25,30,31). In the current study, those patients with a closer tumor to nipple/NAC. This was a requirement that all imaging demonstrate a distance >2 cm (23,26-28). Tumors found to be closer than 2 cm to the NAC, numerous studies have recommended that the NAC during the time period studied.

No patients presented with recurrence in the NAC or nipple areolar complex.

Follow-up ranged between 3 months and 6 years, and only one (1.4%) patient in the cohort who underwent an NSM for cancer ultimately developed a recurrence. This occurred in a patient with a T1N0 tumor, 4.75 cm from the NAC who developed a chest wall recurrence. There were no instances of tumor recurrence within the NAC in the current study.

In the studies demonstrating rates of local recurrence >10%, cancer recurrence in the lymph nodes was included in the rate (19,24). Gerber et al (19) evaluated 246 patients with an indication for MRM who were treated with MRM, SSM or NSM with axillary lymph node dissection, identifying no differences in the rates of local recurrence amongst the three groups after a mean follow-up period of 101 months. More recent studies have demonstrated much lower local recurrence rates, similar to the present findings (16,24). An analysis of 1,006 procedures from the Italian National database of NSM, the local regional recurrence rate was 2.9% with a recurrence rate in the NAC of 0.7% (25). In the present study, a single recurrence occurred, yielding a local recurrence rate of 1.4%. This was a chest wall recurrence in a patient with stage I (T1N0) cancer who did not require adjuvant chemotherapy or radiation following NSM. No patients presented with recurrence in the NAC during the time period studied.

In order to decrease the likelihood of cancer involvement of the NAC, numerous studies have recommended that the tumor to NAC distance on pre-operative imaging be no closer than 2 cm (23,26-28). Tumors found to be closer than 2 cm to the NAC are considered to be a relative contraindication to pursuing NSM. The lower local recurrence rate in the current study is likely due in large part to patient selection, as there was a requirement that all imaging demonstrate a distance >2 cm between the tumor and the NAC. A previous study by Tang et al (29) evaluated their group's experience with positive nipple margins and management, including excision of only the nipple with retention of the areola, and identified that at a 36-month median follow-up, no recurrences occurred in the nipple/NAC. This may expand the indications for NSM in the future.

The complication rate in the present study was 17.3%, which is comparable with the reported literature (21,25,30,31). In the current study, those patients with a closer tumor to nipple/NAC. This was a requirement that all imaging demonstrate a distance >2 cm (23,26-28). Tumors found to be closer than 2 cm to the NAC, numerous studies have recommended that the NAC during the time period studied.

No patients presented with recurrence in the NAC or nipple areolar complex.

Follow-up ranged between 3 months and 6 years, and only one (1.4%) patient in the cohort who underwent an NSM for cancer ultimately developed a recurrence. This occurred in a patient with a T1N0 tumor, 4.75 cm from the NAC who developed a chest wall recurrence. There were no instances of tumor recurrence within the NAC in the current study.

Discussion

The rate of local recurrence in numerous studies of patients undergoing an NSM varies, ranging from 0-25.7% (18,19,23,24). In the studies demonstrating rates of local recurrence >10%, cancer recurrence in the lymph nodes was included in the rate (19,24). Gerber et al (19) evaluated 246 patients with an indication for MRM who were treated with MRM, SSM or NSM with axillary lymph node dissection, identifying no differences in the rates of local recurrence amongst the three groups after a mean follow-up period of 101 months. More recent studies have demonstrated much lower local recurrence rates, similar to the present findings (16,24). An analysis of 1,006 procedures from the Italian National database of NSM, the local regional recurrence rate was 2.9% with a recurrence rate in the NAC of 0.7% (25). In the present study, a single recurrence occurred, yielding a local recurrence rate of 1.4%. This was a chest wall recurrence in a patient with stage I (T1N0) cancer who did not require adjuvant chemotherapy or radiation following NSM. No patients presented with recurrence in the NAC during the time period studied.

In order to decrease the likelihood of cancer involvement of the NAC, numerous studies have recommended that the tumor to NAC distance on pre-operative imaging be no closer than 2 cm (23,26-28). Tumors found to be closer than 2 cm to the NAC are considered to be a relative contraindication to pursuing NSM. The lower local recurrence rate in the current study is likely due in large part to patient selection, as there was a requirement that all imaging demonstrate a distance >2 cm between the tumor and the NAC. A previous study by Tang et al (29) evaluated their group's experience with positive nipple margins and management, including excision of only the nipple with retention of the areola, and identified that at a 36-month median follow-up, no recurrences occurred in the nipple/NAC. This may expand the indications for NSM in the future.

The complication rate in the present study was 17.3%, which is comparable with the reported literature (21,25,30,31). In the current study, those patients with a closer tumor to

Follow-up ranged between 3 months and 6 years, and only one (1.4%) patient in the cohort who underwent an NSM for cancer ultimately developed a recurrence. This occurred in a patient with a T1N0 tumor, 4.75 cm from the NAC who developed a chest wall recurrence. There were no instances of tumor recurrence within the NAC in the current study.

Discussion

The rate of local recurrence in numerous studies of patients undergoing an NSM varies, ranging from 0-25.7% (18,19,23,24). In the studies demonstrating rates of local recurrence >10%, cancer recurrence in the lymph nodes was included in the rate (19,24). Gerber et al (19) evaluated 246 patients with an indication for MRM who were treated with MRM, SSM or NSM with axillary lymph node dissection, identifying no differences in the rates of local recurrence amongst the three groups after a mean follow-up period of 101 months. More recent studies have demonstrated much lower local recurrence rates, similar to the present findings (16,24). An analysis of 1,006 procedures from the Italian National database of NSM, the local regional recurrence rate was 2.9% with a recurrence rate in the NAC of 0.7% (25). In the present study, a single recurrence occurred, yielding a local recurrence rate of 1.4%. This was a chest wall recurrence in a patient with stage I (T1N0) cancer who did not require adjuvant chemotherapy or radiation following NSM. No patients presented with recurrence in the NAC during the time period studied.

In order to decrease the likelihood of cancer involvement of the NAC, numerous studies have recommended that the tumor to NAC distance on pre-operative imaging be no closer than 2 cm (23,26-28). Tumors found to be closer than 2 cm to the NAC are considered to be a relative contraindication to pursuing NSM. The lower local recurrence rate in the current study is likely due in large part to patient selection, as there was a requirement that all imaging demonstrate a distance >2 cm between the tumor and the NAC. A previous study by Tang et al (29) evaluated their group's experience with positive nipple margins and management, including excision of only the nipple with retention of the areola, and identified that at a 36-month median follow-up, no recurrences occurred in the nipple/NAC. This may expand the indications for NSM in the future.

The complication rate in the present study was 17.3%, which is comparable with the reported literature (21,25,30,31). In the current study, those patients with a closer tumor to
time of mastectomy, however immediate reconstruction with a silicone or saline implant following NSM has become more widely accepted in recent years. In a 2010 prospective study of 214 consecutive NSMs with immediate silicone implant reconstruction, the overall complication rate was 16% with 6% requiring explantation of the prostheses due to the complication (22). In 2012 the present study began performing NSM with direct-to-implant reconstruction and in the study period identified no difference in complication rates when a permanent implant was placed at the time of mastectomy in lieu of a tissue expander; however, more patients with direct implant-based reconstruction required removal of their implants. There are limitations to the present study, as it was a retrospective chart review and certain medical data was missing or incomplete. For example, breast weight was only recorded for 106 breast specimens and therefore the current study was unable to delineate whether larger breast size increases complication rates. Although this is a retrospective study, it provides additional data regarding the oncologic safety and low complication rate of NSMs. It is unlikely that a randomized controlled trial may be offered to patients comparing NSM to SSM and MRM, as patients who are candidates for a NSM would not want to be randomized to a less cosmetically pleasing surgery.

In conclusion, the present study adds to the growing literature demonstrating the oncologic safety of NSMs with a local recurrence rate of 1.4% in properly selected patients with tumor to nipple distance >2 cm. Additionally, the current study also demonstrated a low complication rate, including a low rate of nipple-areolar loss with a lateral or inframammary incision. These results further demonstrate that NSMs are safe and do not comprise oncologic outcomes or increase complication rates.

References

29. Tang R, Coopey SB, Merrill AL, Rai U, Specht MC, Gadd MA, 
Colwell AS, Austen WG Jr, Brachtel EF and Smith BL: Positive 
nipple margins in nipple-sparing mastectomies: Rates, manage-

Kronowitz SJ: Impact of surgical techniques, biomaterials, and 
patient variables on rate of nipple necrosis after nipple-sparing 

Tang R, Smith BL and Austen WG Jr: Breast reconstruction 
following nipple-sparing mastectomy: Predictors of complica-
tions, reconstruction outcomes, and 5-year trends. Plast Reconstr 

32. Abedi N, Ho AL, Knox A, Tashakkor Y, Omeis T, Van Laeken N,
Lennox P and Macadam SA: Predictors of mastectomy flap 
necrosis in patients undergoing immediate breast reconstruction: 

33. Matsen CB, Mehrara B, Eaton A, Capko D, Berg A, Stempel M,
necrosis after mastectomy with reconstruction: A prospective 

34. Petersen A, Eftekhar AL and Damsgaard TE: Immediate breast 
reconstruction: A retrospective study with emphasis on compli-
2012.

35. Bertoni DM, Nguyen D, Rochlin D, Hernandez-Boussard T,
Meyer S, Choy N, Gurtner GC and Wapnir IL: Protecting nipple 
perfusion by devascularization and surgical delay in patients at 
risk for ischemic complications during nipple-sparing mastecto-

36. Chung CU, Wink JD, Nelson JA, Fischer JP, Serletti JM 
and Kanchwala SK: Surgical site infections after free flap 
breast reconstruction: An analysis of 2,899 patients from the 

37. Garwood ER, Moore D, Ewing C, Hwang ES, Alvarado M,
Foster RD and Esserman LJ: Total skin-sparing mastectomy: 
Complications and local recurrence rates in 2 cohorts of patients. 